Generalized Anxiety DisorderMANAGEMENT

PSYCHIATRIC PRESENTATIONS · 12 SECTIONS

⚲

682 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Acute anxiety Acute psychosis Agitation-behavioral emergency Anorexia Nervosa (Medical Complications)Bipolar disorder Bipolar Disorder (Depressive Episode)Bipolar Disorder (Manic Episode)Bulimia Nervosa (Medical Complications)Catatonia Conversion disorder Dementia and behavioral crisis Factitious Disorder Failure to Cope (Social)Failure to Thrive Generalized Anxiety Disorder Homicidal Ideation Major Depressive Disorder Major depressive episode Malingering Neuroleptic malignant syndrome Panic Attack Post-Traumatic Stress Disorder (Acute)Schizophrenia Exacerbation Suicidal Ideation Suicidal ideation and attempt Suicide Attempt

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp33

Immediate safety priorities

›Suicidality and safety screen

›Active suicidal ideation with plan or intent — immediate psychiatric evaluation

›GAD associated with suicidal ideation and attempts even without comorbid depression

›Co-occurring anxiety and depression significantly elevates suicide attempt risk

›Self-harm urges or recent attempt — escalate to resuscitation bay or secure setting

›Mental health crisis consultation

›Remove means from immediate access

›Agitation or behavioral emergency

›Verbal de-escalation first-line

›Lorazepam 1–2 mg IV/IM if severe agitation poses safety risk

Ruling out medical emergencies

›Cannot-miss medical etiologies requiring immediate workup

›Acute chest pain, severe dyspnea, or syncope

›ECG and cardiac monitoring

›Pulmonary embolism workup if pretest probability elevated

›Episodic hypertension with headache, diaphoresis, and palpitations

›Pheochromocytoma must be excluded before discharge

›24-hour urine metanephrines or plasma free metanephrines

›Tachycardia with tremor, weight loss, heat intolerance

›Hyperthyroidism — TSH required

›Thyroid storm if hemodynamically unstable

›New neurologic symptoms (vertigo, amnesia, slurred speech, loss of bowel/bladder control)

›Onset after age 45 increases probability of organic etiology

›CT head or MRI brain as appropriate

Escalation triggers

›Triggers requiring inpatient disposition

›Suicidal ideation with intent or plan

02History/hx90

Chief complaint and symptom characterization

›Presenting concern

›Excessive, uncontrollable worry about multiple domains (finances, health, family, work, minor matters)

›More days than not for at least 6 months

›Patients may self-describe as lifelong "worrywart"

›Physical somatic complaints as predominant presenting symptom

›Headaches, GI distress, insomnia, muscle tension most common in primary care and ED

›Patients rarely self-report "worry" — somatic complaints lead presentation

›Screening question: "Do you worry excessively about minor matters?" — affirmative is highly suggestive

Associated symptoms (DSM-5 criteria)

›Core associated symptom cluster (requires at least 3 of 6)

›Restlessness or feeling on edge

›Keyed-up sensation

›Inability to relax

›Easy fatigability

›Disproportionate to activity level

›Difficulty concentrating or mind going blank

›Functional impact on work and daily tasks

›Irritability

›Interpersonal conflict

›Low frustration tolerance

›Muscle tension

›Chronic neck, shoulder, or back tension

›TMJ symptoms

›Sleep disturbance

›Difficulty falling or staying asleep

›Early morning awakening

Alarm features

›Red flag symptoms prompting urgent medical workup

›Episodic severe hypertension with headache, diaphoresis, palpitations

›Pheochromocytoma until proven otherwise

›Weight loss, heat intolerance, tremor, tachycardia

›Hyperthyroidism

›Onset after age 45 with no prior anxiety history

›Higher suspicion for underlying organic etiology

›Vertigo, syncope, amnesia, slurred speech

›Neurologic process must be excluded

›Psychotic features (hallucinations, delusions)

›Alternative psychiatric diagnosis

Functional impairment

›Impact on daily functioning

›Work or academic performance deterioration

›Absenteeism or presenteeism

›Relationship strain

›Withdrawal from social activities

›Self-care and daily activity difficulty

›Difficulty completing routine tasks

Review of systems

›System-by-system symptom screen

›Psychiatric: depressed mood, anhedonia, panic attacks, obsessions, trauma history, phobias

›Persistent anhedonia distinguishes MDD from GAD — not a GAD symptom

›Cardiovascular: palpitations, chest pain, tachycardia

›Gastrointestinal: nausea, abdominal pain, diarrhea, IBS symptoms

›Neurologic: headaches, dizziness, tremor, paresthesias, concentration difficulties

›Endocrine: heat or cold intolerance, weight changes, menstrual irregularities

›Respiratory: dyspnea, hyperventilation episodes

›Musculoskeletal: muscle tension, chronic pain

›Sleep: insomnia, restless sleep, early morning awakening

Past psychiatric and medical history

›Psychiatric history

›Prior anxiety episodes and treatment response

›Adequacy of prior trials: dose, duration, premature discontinuation

›History of depression, bipolar disorder, PTSD, or other psychiatric conditions

›Prior psychiatric hospitalizations or suicide attempts

›Substance use history: alcohol, cannabis, stimulants, benzodiazepines

›Medical history

›Thyroid disease, cardiac arrhythmias, COPD, chronic pain, IBS, diabetes

›Chronic medical conditions are independent risk factors for GAD

›Surgical history, particularly thyroid or cardiac

Medications and substance exposure

›Medications causing or worsening anxiety

›Corticosteroids, sympathomimetics, stimulants, bronchodilators, decongestants

›Levothyroxine (especially supratherapeutic doses)

›Benzodiazepine or alcohol withdrawal

›Caffeine and stimulant intake

›Energy drink and supplement use

›Heavy caffeine consumption may represent caffeine-induced anxiety disorder

Social history and risk factors

›Demographic and social risk factors

›Female sex — 2 to 3 times more likely than males

›Low socioeconomic status

›Widowed or divorced marital status

›Occupational stress and financial pressures

›Childhood adversity

›Physical or sexual abuse, neglect

›Parental intimate-partner violence

›Overprotective parenting style

›Temperament and psychological factors

›Behavioral inhibition and harm avoidance temperament

›Intolerance of uncertainty — relatively specific psychological construct for GAD

›Alcohol and substance use as self-medication

›Screen directly: "Do you use alcohol or drugs to reduce anxiety?"

›Prevalence of substance use disorder approximately 16.5% in anxiety disorder patients

Family history

›Familial risk

›Parental GAD confers hazard ratio 3.77 for offspring GAD

›Heritability estimated at 30 to 35%

›Parental depression, substance use disorders, or other mental illness

›Behavioral inhibition in childhood as precursor

03Physical Exam/exam52

Vital signs

›Hemodynamic and autonomic assessment

›Heart rate

›Tachycardia may reflect anxiety, hyperthyroidism, arrhythmia, or pheochromocytoma

›Resting rate >100 bpm warrants further workup

›Blood pressure

›Episodic hypertension points toward pheochromocytoma

›Situational elevation common in anxiety presentations

›Respiratory rate

›Tachypnea and hyperventilation pattern

›Associated perioral or fingertip paresthesias

Thyroid and neck exam

›Thyroid assessment

›Thyroid size, consistency, nodules

›Enlarged or nodular gland — concern for thyroid disease

›Exophthalmos or lid lag

›Graves disease features

›Fine tremor of outstretched hands

›Hyperthyroidism marker

Cardiovascular exam

›Cardiac auscultation and rhythm

›Irregular rhythm

›Atrial fibrillation or frequent ectopy

›Murmurs

›Valvular disease — mitral valve prolapse has anxiety association

›Extra heart sounds or signs of heart failure

Neurologic exam

›Neurologic screen

04Differential Diagnosis/ddx43

Psychiatric mimics

›Major depressive disorder (ICD-10 F32, F33)

›Significant symptom overlap with GAD

›Persistent anhedonia is characteristic of MDD but not GAD

›Comorbidity rate 43% — both diagnoses can coexist

›Panic disorder (ICD-10 F41.0)

›Recurrent unexpected panic attacks with sudden onset and crescendo course

›GAD worry-triggered panic attacks do not qualify as panic disorder

›Prominent avoidance behavior in panic disorder

›Social anxiety disorder (ICD-10 F40.10)

›Fear focused specifically on social or performance situations and evaluation by others

›GAD worry is multifocal; social anxiety is situationally bound

›PTSD (ICD-10 F43.10)

›Temporally linked to traumatic event with reexperiencing symptoms

›Hypervigilance and avoidance overlap with GAD

›OCD (ICD-10 F42)

›Intrusive unwanted thoughts with compulsions

›GAD features future-oriented worry; OCD features ego-dystonic obsessions

›Illness anxiety disorder (ICD-10 F45.21)

›Health-focused worry exclusively

›GAD worry is multifocal, not restricted to health

›Bipolar disorder (ICD-10 F31)

›Manic or hypomanic episodes may present with anxiety and racing thoughts

›Mood elevation, decreased sleep need, grandiosity differentiating features

›Substance-induced anxiety disorder (ICD-10 F10–F19 range)

›Anxiety only in context of intoxication or withdrawal

›Caffeine, stimulants, cannabis, cocaine, alcohol, benzodiazepine withdrawal

05Laboratory Tests/lt45

Thyroid function

›TSH (thyroid stimulating hormone)

›First-line test to exclude hyperthyroidism and hypothyroidism

›Suppressed TSH with elevated free T4 confirms hyperthyroidism

›Anxiety symptoms from hyperthyroidism indistinguishable from GAD clinically

›Order in all new anxiety presentations without prior documented normal TSH

Metabolic screen

›Comprehensive metabolic panel

›Electrolytes and glucose

›Hypoglycemia excluded by fasting glucose

›Hypocalcemia and hypomagnesemia cause anxiety and palpitations

›Renal function

›Uremia can present with anxiety and neuropsychiatric symptoms

›Liver function

›Hepatic encephalopathy and Wilson disease in differential

Blood count and inflammatory markers

›Complete blood count

›Anemia — fatigue, palpitations, shortness of breath overlap

›Iron deficiency anemia particularly common in women of reproductive age

›Infection or inflammatory state

›Elevated white count may point to systemic illness driving symptoms

Pheochromocytoma workup

›Catecholamine metabolites when episodic features present

›Plasma free metanephrines — preferred first-line test

›Sensitivity >97% for pheochromocytoma

›Collected in supine resting state for accuracy

›24-hour urine metanephrines and catecholamines — alternative or confirmatory

›False positives with tricyclics, acetaminophen, sympathomimetics

06Diagnostic Tests/dt57

Scoring Systems

›GAD-7 scoring and clinical application

›7-item self-report scale measuring anxiety severity

›Each item scored 0–3 (not at all, several days, more than half the days, nearly every day)

›Total score 0–21

›Sensitivity 89%, specificity 82% at cutoff ≥10 for GAD diagnosis

›Severity tiers guide treatment intensity

›Mild (5–9): psychoeducation and lifestyle modification

›Moderate (10–14): pharmacotherapy and/or CBT

›Severe (≥15): combined pharmacotherapy plus psychotherapy; consider psychiatry referral

›Serial GAD-7 monthly to track treatment response

›Target at least 50% reduction in score indicating meaningful response

›If <50% improvement at 3 months — consider referral or treatment adjustment

›Hamilton Anxiety Rating Scale (HAM-A)

›14-item clinician-administered scale

›Score >17 indicates moderate to severe anxiety

›Useful for clinical trials and treatment monitoring

›Somatic and psychic anxiety subscales

›Penn State Worry Questionnaire (PSWQ)

›16-item self-report measure of worry severity and generalization

›Distinguishes GAD-level worry from normal adaptive worry

›Useful for confirming GAD phenotype when diagnosis uncertain

MRI

›MRI brain in select cases

›Indications for neuroimaging in anxiety presentations

›New onset after age 45 without prior anxiety history

›Focal neurologic signs or symptoms on examination

›Cognitive impairment out of proportion to anxiety severity

07Disposition/dispo34

Discharge criteria

›Safe discharge parameters

›No active suicidal ideation, plan, or intent

›Safety plan discussed and documented

›No acute medical emergency identified or excluded and workup plan established

›Able to follow up with primary care or mental health provider

›Follow-up appointment arranged or patient able to arrange

›Patient education provided on diagnosis, treatment, and return precautions

›Prescription plan or bridge to outpatient care established

Admission criteria

›Inpatient admission indications

›Active suicidal ideation with plan, intent, or recent attempt

›Psychiatric hold and inpatient psychiatric admission

›Comorbid severe depression with safety concerns

›Inpatient psychiatric unit

›Severe functional impairment — unable to care for self or maintain safety

›Acute medical condition requiring inpatient workup

›Suspected pheochromocytoma with hemodynamic instability

›New cardiac arrhythmia requiring monitoring

›Medically supervised detoxification requirement

›Alcohol or benzodiazepine withdrawal with moderate to severe symptoms

Outpatient follow-up

›Follow-up timing and monitoring

›2–4 weeks after initiating or changing medication

›Tolerability and early treatment response assessment

›Serial GAD-7 monthly to track symptom trajectory

›Reassess at 4–6 weeks per dose level — further titration if partial response

›After stabilization: follow-up every 1–3 months

08Treatment/t109

Immediate stabilization (ED and acute setting)

›Acute anxiety management

›Reassurance and psychoeducation

›Calm, non-stimulating environment

›Explain physical symptoms as anxiety manifestations

›Normalize anxiety as a treatable medical condition

›Breathing techniques for acute distress

›Diaphragmatic breathing: 4 seconds in, hold 4, out 6

›Reduces hyperventilation-driven somatic symptoms

›Short-term benzodiazepine if severe acute distress

›Lorazepam 0.5–1 mg orally or 0.5–1 mg IV/IM

›Limit to single acute-setting dose with clear follow-up plan

›Avoid initiating ongoing benzodiazepine prescription from ED

First-line pharmacotherapy (SSRI)

›Escitalopram (FDA-approved for GAD)

›Starting dose 5–10 mg orally once daily

›Target dose 10–20 mg daily

›Titrate every 4–6 weeks based on response and tolerability

›QTc check at higher doses (>20 mg)

›Time to benefit: 2–4 weeks onset; full effect up to 3 months

›Sertraline (off-label, widely used)

›Starting dose 25–50 mg orally once daily

›Target dose 50–200 mg daily

›Titrate every 4–6 weeks

›Paroxetine (FDA-approved for GAD)

›Starting dose 10–20 mg orally once daily

›Target dose 20–50 mg daily

›Anticholinergic effects and discontinuation syndrome — use caution in elderly

›Fluoxetine (off-label)

›Starting dose 10–20 mg orally once daily

›Target dose 20–80 mg daily

›Longer half-life reduces discontinuation syndrome risk

First-line pharmacotherapy (SNRI)

›Duloxetine (FDA-approved for GAD)

›Starting dose 30 mg orally once daily

›Target dose 60–120 mg daily

›Titrate after 2 weeks to 60 mg; further if needed at 4–6 weeks

›Benefit for comorbid chronic pain — dual advantage

›Venlafaxine XR (FDA-approved for GAD)

›Starting dose 37.5–75 mg orally once daily

›Target dose 75–225 mg daily

›Blood pressure monitoring — noradrenergic effect at higher doses

›Taper slowly on discontinuation to avoid withdrawal syndrome

Key prescribing principles

›Start low, go slow approach

›Patients with anxiety are sensitive to side effects that mimic anxiety

›Jitteriness, palpitations, insomnia common in first 1–2 weeks

›Warn patients in advance to prevent premature discontinuation

›Allow 4–6 weeks per dose to assess benefit before dose escalation

›Full treatment effect may take up to 3 months

›Treatment duration

›Continue treatment at least 12 months to minimize relapse

›Discontinuing before 1 year leads to relapse in up to 50% of patients

›Taper slowly over weeks to months when discontinuing

›Avoid abrupt discontinuation — withdrawal syndrome risk

Second-line and adjunctive pharmacotherapy

›Buspirone

›Starting dose 5 mg three times daily

›Titrate to 15–60 mg per day in divided doses

›No dependence risk — preferred over benzodiazepines for chronic use

›Delayed onset 2–4 weeks — set patient expectations

›Less effective in patients with recent benzodiazepine use

›Pregabalin

›Starting dose 50 mg three times daily

›Target dose 150–600 mg daily in divided doses

›Evidence of efficacy for GAD; Class IIa recommendation

›Side effects: weight gain, sedation, dizziness

›Try antidepressants first; use as adjunctive or second-line

›Hydroxyzine (off-label acute adjunct)

›25–50 mg orally up to four times daily as needed

›Non-addictive anxiolytic; useful as needed for acute exacerbations

›Sedation and anticholinergic effects limit use

Medications to avoid or use with caution

›Benzodiazepines

›Not first-line for GAD

›Risk of physical dependence and withdrawal

›Rebound anxiety on discontinuation

›Avoid in patients with alcohol or substance use disorder

›Never as monotherapy for GAD

›If used, limit duration and have tapering plan

›Quetiapine

›Efficacious but poorly tolerated at therapeutic doses

›Metabolic side effects, sedation, weight gain

›Not recommended as first-line; consider only if multiple agents have failed

›Bupropion and vortioxetine

›Inconsistent or insufficient evidence for GAD

›Not recommended

Psychotherapy

›Cognitive Behavioral Therapy (CBT)

›Most effective and well-studied psychotherapy for GAD

›Response rate 46–60% with CBT alone

›Can be used alone for mild to moderate GAD

›Combined with pharmacotherapy for moderate to severe GAD

›Core CBT components for GAD

›Cognitive restructuring — challenging worry-based thoughts

›Worry exposure and postponement techniques

›Relaxation training: progressive muscle relaxation

›Problem-solving skills training

›Acceptance and Commitment Therapy (ACT)

›Effective alternative or adjunctive to CBT

›Focuses on acceptance of worry rather than elimination

›Mindfulness-Based Stress Reduction (MBSR)

›Emerging evidence for GAD benefit

›8-week structured program

›Reduces rumination and physiologic arousal

Lifestyle interventions

›Evidence-supported adjunctive measures

›Regular aerobic exercise

›30 minutes at least 3–5 times weekly

›Evidence supports anxiolytic benefit equivalent to some medications

›Caffeine reduction

›Heavy caffeine intake exacerbates anxiety and can mimic GAD

›Alcohol avoidance

›Alcohol worsens anxiety long-term despite short-term relief

›Sleep hygiene

›Consistent sleep schedule

›Screen exposure reduction before bed

09Special Populations/sp72

Pregnancy

›GAD in pregnancy considerations

›Prevalence and screening

›Anxiety disorders affect approximately 15% of pregnant women

›Screen with GAD-7 at first prenatal visit and postpartum

›Untreated anxiety in pregnancy associated with preterm birth and low birth weight

›Pharmacotherapy safety

›SSRIs — generally preferred over untreated severe anxiety

›Sertraline and escitalopram have largest safety data in pregnancy

›Risk of neonatal adaptation syndrome with third-trimester exposure — neonatal monitoring

›Persistent pulmonary hypertension of newborn — small absolute risk with SSRI late pregnancy

›SNRIs — venlafaxine and duloxetine limited data; similar considerations to SSRIs

›Buspirone — limited human data; avoid if alternatives available

›Benzodiazepines — avoid in first trimester (cleft palate risk debated); neonatal withdrawal with chronic use

›Paroxetine — FDA category D; associated with cardiac malformations (Category D)

›Non-pharmacological approaches preferred first-line when possible

›CBT safe and effective in pregnancy

›Mindfulness-based interventions with emerging evidence

›Postpartum period

›High risk of GAD exacerbation and postpartum anxiety disorder

›Screen at 6-week and 12-week postpartum visits

›SSRIs compatible with breastfeeding — sertraline preferred (lowest breast milk transfer)

Geriatric

›GAD in older adults

›Prevalence and recognition

›GAD prevalence 3–10% in adults over 65

›Underdiagnosed — symptoms attributed to normal aging or medical comorbidities

›Somatic presentations even more predominant than in younger adults

›Pharmacotherapy modifications

›Start at half the standard adult dose

›Escitalopram 5 mg daily starting dose; max 10 mg daily in elderly

›Reduced renal and hepatic clearance prolongs drug half-life

›Avoid paroxetine in elderly — high anticholinergic burden (Beers Criteria)

›Avoid benzodiazepines in elderly — Beers Criteria high-risk medication

›Falls, hip fracture, cognitive impairment, paradoxical agitation

›Buspirone well-tolerated alternative in elderly

›Start 5 mg twice daily; titrate cautiously

›Pregabalin — sedation and fall risk require careful monitoring

›Comorbidity considerations

›Higher burden of comorbid medical illness in elderly GAD

›Cardiovascular disease, COPD, chronic pain — all increase GAD risk and complicate treatment

›Cognitive assessment — anxiety and early dementia can co-occur and interact

›Drug-drug interaction risk higher with polypharmacy

›Non-pharmacological approaches

›CBT effective in elderly — may require modified pacing and session length

›Relaxation techniques, mindfulness, activity scheduling

Pediatrics

›GAD in children and adolescents

›Presentation differences

›Children may present with recurrent abdominal pain, headaches, school avoidance

›Worry themes: academic performance, punctuality, natural disasters, family safety

›Younger children may require parent collateral for symptom characterization

›Behavioral inhibition in early childhood is a risk factor and precursor

›Diagnosis

›DSM-5 requires only 1 of 6 associated symptoms in children vs 3 in adults

›GAD-7 validated for adolescents age 13 and above

›Childhood anxiety multidimensional scale (MASC) for younger children

›Pharmacotherapy

›SSRIs first-line — fluoxetine and sertraline have best pediatric data

›Fluoxetine: 5–10 mg daily starting; target 20–40 mg daily

›Sertraline: 12.5–25 mg daily starting; target 50–200 mg daily

›FDA black box warning: SSRIs increase suicidal ideation risk in children and adolescents

›Monitor closely in first 4 weeks — weekly contact recommended

›Clinical benefit typically outweighs risk in moderate to severe GAD

›Venlafaxine XR: evidence for pediatric GAD; starting 37.5 mg daily

›Benzodiazepines not recommended in pediatric anxiety — dependence risk

›Buspirone limited evidence in children; not first-line

›Psychotherapy

›CBT is first-line and most evidence-based for pediatric GAD

›Parent involvement in therapy improves outcomes

›Exposure-based CBT with rewards system for children

›Combined CBT plus SSRI more effective than either alone for moderate-severe pediatric GAD

›School involvement

›School-based accommodations may support function during acute phase

›Avoid excessive accommodation that reinforces avoidance

10Background/b80

Epidemiology

›Prevalence and incidence

›Lifetime prevalence approximately 9% globally

›12-month prevalence 3–5% in general population

›7–8% of primary care patients have GAD

›Sex distribution

›Women 2–3 times more likely to be diagnosed than men

›Female predominance persists across all age groups

›Age of onset

›Median age of onset approximately 30 years

›Earlier onset (childhood or early adulthood) predicts more severe chronic course

›Late-onset (>45 years) — higher suspicion for medical etiology

›Comorbidity burden

›Comorbid MDD in 43% of GAD patients over lifetime

›Comorbid substance use disorder approximately 16.5%

›Comorbid other anxiety disorders common

›Increased cardiovascular morbidity and mortality in GAD

›Functional and economic impact

›GAD associated with significant functional disability, work absenteeism

›Among the most costly mental health conditions to healthcare systems

›Risk of chronic course — remission rates lower than for other anxiety disorders

Pathophysiology

›Neurobiological mechanisms

›Amygdala hyperreactivity

›Exaggerated threat detection and fear response

›Impaired prefrontal cortical modulation of amygdala

›Serotonin system dysregulation

›Reduced serotonergic tone in limbic and cortical circuits

›Basis for SSRI and SNRI efficacy

›Noradrenergic system activation

›Elevated locus coeruleus firing drives autonomic arousal symptoms

›Tachycardia, diaphoresis, tremor — noradrenergic mediated

›Hypothalamic-pituitary-adrenal (HPA) axis dysregulation

›Elevated basal cortisol in some GAD patients

›Chronic cortisol exposure contributes to comorbid depression and cognitive effects

›GABAergic system

›Reduced inhibitory GABA tone — basis for benzodiazepine and pregabalin activity

›Pregabalin binds alpha-2-delta subunit of voltage-gated calcium channels

›Psychological models

›Intolerance of uncertainty model

›Core psychological vulnerability relatively specific to GAD

›Worry functions as cognitive avoidance of uncertain negative outcomes

›Metacognitive model

›Positive beliefs about worry utility ("worrying keeps me safe") perpetuate GAD

›Negative beliefs about worry controllability drive distress

›Emotional avoidance model

›Worry serves to suppress more distressing emotional imagery and processing

›Genetic and developmental factors

›Heritability estimated at 30–35%

›Parental GAD confers hazard ratio 3.77 for offspring

›Shared genetic factors with major depression and neuroticism

›Childhood behavioral inhibition as temperamental precursor

›Early environmental stressors interact with genetic vulnerability

Therapeutic Considerations

›Treatment selection framework

›Mild GAD (GAD-7 5–9)

›Psychoeducation, lifestyle modification, and watchful waiting

›Brief behavioral intervention as first step

›Moderate GAD (GAD-7 10–14)

›Pharmacotherapy and/or CBT — patient preference guides

›Combined approach superior to either alone

›Severe GAD (GAD-7 ≥15)

›Combined SSRI/SNRI plus CBT

›Psychiatry referral if inadequate response at 3 months

›Pharmacotherapy evidence base

›SSRIs and SNRIs — Class I recommendation for GAD pharmacotherapy

›Network meta-analysis confirms escitalopram, duloxetine, venlafaxine as among most effective

›Number needed to treat for response approximately 5–7

›Buspirone — effective monotherapy or adjunct without dependence risk

›Inferior to SSRIs in patients with prior benzodiazepine use

›Pregabalin — evidence base supports efficacy; role as adjunctive agent

›Benzodiazepines — short-term efficacy only; long-term harms outweigh benefits

›Psychotherapy evidence base

›CBT is the most evidence-based psychotherapy for GAD

›Response rate 46–60%; comparable to pharmacotherapy at long-term follow-up

›CBT + pharmacotherapy superior to either alone for moderate-severe GAD

›Internet-delivered CBT (iCBT) — comparable efficacy to face-to-face in RCTs

›Scalable option for patients with access barriers

›Monitoring and treatment optimization

›Serial GAD-7 to track response — target at least 50% score reduction

›If inadequate response after adequate trial — switch within class or augment

›Minimum 12-month treatment duration to prevent relapse

›Relapse risk up to 50% if discontinued before 1 year

11Patient Discharge Instructions/pdi31

copy discharge instructions

›Discharge instructions for Generalized Anxiety Disorder

›What is Generalized Anxiety Disorder?

›GAD is a common, treatable medical condition characterized by persistent, excessive worry about multiple areas of life

›Symptoms include restlessness, fatigue, difficulty concentrating, irritability, muscle tension, and sleep difficulties

›Physical symptoms such as headaches, stomach upset, and muscle pain are very common

›GAD responds well to treatment — most people improve significantly with appropriate care

›Your medications

›Take your prescribed medication every day as directed — do not skip doses

›Anxiety medications take 2–4 weeks to begin working; full benefit may take 2–3 months

›Early side effects (nausea, jitteriness, sleep changes) are common and usually improve within 2 weeks

›Do not stop your medication abruptly — always taper under your doctor's guidance

›Avoid alcohol — it worsens anxiety in the long run and interacts with your medications

›Reduce or eliminate caffeine — it can significantly worsen anxiety symptoms

›Lifestyle recommendations

›Regular aerobic exercise at least 3–5 times per week has proven anxiolytic benefit

›Maintain consistent sleep schedule — go to bed and wake at the same time daily

›Practice diaphragmatic breathing: breathe in for 4 seconds, hold 2, out for 6 seconds

›Reduce screen time before bed — aim for a device-free hour before sleep

›Reach out to a counselor or therapist for CBT — the most effective anxiety therapy

›Follow-up instructions

›Follow up with your doctor in 2–4 weeks after starting or changing medication

›If you cannot get an appointment quickly, call your doctor if side effects are troublesome

›Consider asking your doctor for a referral to a therapist specializing in cognitive behavioral therapy

›Return to emergency department if any of the following occur

›Thoughts of harming yourself or others — call 988 (Suicide and Crisis Lifeline) or go to nearest ED immediately

›Severe chest pain, difficulty breathing, or heart racing that does not settle within minutes

›Fainting or loss of consciousness

12References/r36

Guidelines and key sources

›Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)

›American Psychiatric Association, 2013 (updated 2022)

›Diagnostic criteria for GAD: ≥6 months of excessive worry, difficult to control, with ≥3 of 6 associated symptoms

›ICD-10 code: F41.1 — Generalized Anxiety Disorder

›Stein MB, Sareen J. Generalized Anxiety Disorder. New England Journal of Medicine. 2015

›Comprehensive clinical review with treatment algorithm

›SSRI/SNRI first-line; CBT equivalent efficacy to pharmacotherapy

›Minimum 12-month treatment to prevent relapse

›Szuhany KL, Simon NM. Anxiety Disorders: A Review. JAMA. 2022

›Updated treatment evidence review

›Combined CBT plus pharmacotherapy superior to either alone for moderate-severe GAD

›Intolerance of uncertainty model evidence base

›Shepardson RL et al. Treatment of Anxiety for Adults in Primary Care Settings. JAMA Internal Medicine. 2026

›Clinical algorithm for anxiety management in primary care

›Quetiapine efficacious but poorly tolerated — not first-line

›Bupropion and vortioxetine inconsistent evidence — not recommended

›Slee A et al. Pharmacological Treatments for Generalised Anxiety Disorder: Systematic Review and Network Meta-Analysis. Lancet. 2019

›Network meta-analysis of pharmacotherapy options

›Escitalopram, duloxetine, venlafaxine among most effective options

›Benzodiazepines effective short-term but long-term harms outweigh benefits

›US Preventive Services Task Force. Screening for Anxiety Disorders in Adults. JAMA. 2023

›USPSTF recommends screening adults under 65 for anxiety disorders

›GAD-7 recommended as primary screening tool

›Insufficient evidence for screening adults 65 and older

›Walter HJ et al. Clinical Practice Guideline for Assessment and Treatment of Children and Adolescents with Anxiety Disorders. JAACAP. 2020

›Pediatric anxiety treatment guidelines

›CBT first-line; SSRI for moderate-severe; combined superior to either alone

Learn More: Generalized Anxiety Disorder→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.